RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive ...

Recursion Pharmaceuticals (NASDAQ:RXRX) outlined its strategy, clinical pipeline and partnership progress at Morgan Stanley’s ...

Najat Khan, PhD, Recursion Pharmaceuticals chief R&D officer and chief commercial officer With at least seven of its programs expected to begin human trials or read out clinical data during 2025, ...

Recursion Pharmaceuticals also said it plans to prioritize treatments for rare diseases within its pipeline while seeking drugmaker partnerships in areas including immunotherapy, oncology, aging and ...

Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...

On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...

Recursion Pharmaceuticals has agreed to acquire the Oxford, U.K.-based artificial intelligence (AI) drug pioneer Exscientia, the companies said today, in a deal that consolidates two leaders in ...

The first list of instructions is obeyed on the way up the spiral i.e. as the instances of the function are being built and the second list is obeyed on the way back down the spiral as the instances ...